Prognostic and clinicopathological significance of ubiquitin-specific protease 22 overexpression in cancers: evidence from a meta-analysis

Ao, Ning; Wang, Liang; Liu, Yuqin

doi:10.2147/ott.s139458

Cited by 3 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of SIRT1 in cancer, including PTC patients, has been extensively studied over the past decade. Increased thyroid tissue SIRT1 expression has been found to be associated with cancer progression and worse prognosis for PTC patients [55]. In our study, increased SIRT1 concentrations were demonstrated in PTC patients allocated to RAI, which is consistent with the results presented by other authors [56].…”

Section: Discussionsupporting

confidence: 93%

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients

Buczyńska

Sidorkiewicz

Kościuszko

et al. 2023

Cancers

View full text Add to dashboard Cite

Total oxidative status (TOS), total antioxidant capacity (TAC), tumor protein 53 (p53), nuclear factor kappa B (NF-κB), forkhead box protein O1 (FOXO), and sirtuin 1 (SIRT1) play crucial roles in oxidative homeostasis and the progression of papillary thyroid cancer (PTC), as previously demonstrated in the literature. Therefore, profiling these markers among PTC patients may be useful in determining their eligibility for radioiodine (RAI) treatment. Since treatment indications are based on multiple and dynamic recommendations, additional criteria for adjuvant RAI therapy are still needed. In our study, we evaluated the TOS, TAC, and serum concentrations of p53, NF-κB, FOXO, and SIRT1 to analyze the relationship between oxidative status and qualification for RAI treatment. For the purpose of this study, we enrolled 60 patients with PTC allocated for RAI treatment as the study group and 25 very low-risk PTC patients not allocated for RAI treatment as a reference group. The serum TOS and SIRT1 concentrations were significantly higher in the study group compared to the reference group (both p < 0.001), whereas the TAC and p53, NK-κB, and FOXO concentrations were significantly lower (all p < 0.05). We also demonstrated the diagnostic utility of TAC (AUC = 0.987), FOXO (AUC = 0.648), TOS (AUC = 0.664), SIRT1 (AUC = 0.709), p53 (AUC = 0.664), and NF-κB (AUC = 0.651) measurements as indications for RAI treatment based on American Thyroid Association recommendations. Our study revealed that oxidative status-related markers may become additional criteria for RAI treatment in PTC patients.

show abstract

Section: Discussionsupporting

confidence: 93%

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients

Buczyńska

Sidorkiewicz

Kościuszko

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer is a group of diseases involving abnormal cell growth and having the capacity to invade or metastasize to other body parts. [ 9 ] The factors favoring prognosis of OSCC include patient-related factors, tumor-related factors, and treatment-related factors. Among tumor-related factors, molecular markers play a crucial role in determining the prognosis of OSCC.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of USP22 and Ki-67 expression in oral squamous cell carcinoma: An immunohistochemical study

Apoorva,

Ananthaneni,

Kumar

et al. 2023

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

Background and Aim: USP22 is a positive regulator in tumor growth, its depletion leads to cell cycle arrest at G1 phase. USP22 over expression was positively correlated with proteins involved in proliferation and negatively correlated with tumor suppressor protein tumor supprn. Ki-67 expression is associated with USP22 over expression in oral squamous cell carcinoma (OSCC) and also in cervical and prostate cancers. The aim of this study is to evaluate the expression of USP22 and Ki-67 in OSCC by using an immunohistochemical staining procedure. Materials and Methods: Immunohistochemistry was used to determine the expression of USP22 protein in 50 archival tissue blocks of histopathologically diagnosed OSCC and 15 normal oral mucosa tissue blocks. The histopathological correlation of USP22 with Ki-67 was done. Results: Expression of USP22 and Ki-67 was seen in the nuclei of epithelial cells. Statistical analysis of the mean expression of USP22 in OSCC and normal tissue showed a significant difference (P = 0.000000119). A significant difference was also observed in Ki-67 between OSCC and normal tissue (P = 0.00000086). Correlation test showed a weak correlation (R = 0.19) between USP22 and Ki-67 expression of group 1. Similarly, a weak correlation (R = 0.51) was observed in group 2. Conclusion: A statistically significant difference in the expression of USP22 and Ki-67 was observed between normal mucosa and OSCC. It can be used in early diagnosis of OSCC but its use as a prognostic indicator is questionable and should be exemplified with a larger study sample.

show abstract

“…USP family member USP22 is highly expressed in multiple malignant tumors, including gastric, colon and prostate cancers (6). The expression level of USP22 is closely associated with metastasis potential, chemotherapeutic resistance and prognosis in patients with cancer (7). USP22 deficiency results in myeloid leukemia via an ETS-family transcription factor pu.1-dependent mechanism after the activation of carcinogenic Kras (8).…”

Section: Introductionmentioning

confidence: 99%

USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin

et al. 2020

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the commonest urological tumors. The incidence of RCC ranks third among urological tumors, after prostate cancer and bladder tumors. However, the etiology of RCC remains unclear. Ubiquitin-specific protease 22 (USP22), a potential marker of cancer stem cells, is associated with the occurrence and progression of numerous tumors. However, the roles of USP22 in RCC have not yet been investigated. Survivin is a member of the inhibitor of apoptotic protein family involved in RCC progression. The present study first detected the expression of USP22 and survivin in RCC tissues using immunohistochemistry and western blotting. It was revealed that the protein levels of USP22 and survivin in RCC tissues were higher than those in adjacent normal renal tissue. Subsequently, it was demonstrated that USP22 knockdown inhibited the growth of an RCC cell line ACHN and downregulated the protein level of survivin, accompanied by an increased level of cleaved-caspase-3. By contrast, overexpression of USP22 promoted the growth of ACHN cells, upregulated the expression of survivin and decreased the level of cleaved-caspase-3. Notably, the changes in USP22 expression did not affect the SURVIVIN mRNA level. Finally, it was confirmed that USP22 interacted with survivin and stabilized it by downregulating its ubiquitination. The present results indicate that USP22 may regulate survivin via deubiquitination, thereby promoting the proliferation of RCC cells. The results of the current study suggest that USP22 may represent a novel therapeutic target for patients with RCC.

show abstract

Prognostic and clinicopathological significance of ubiquitin-specific protease 22 overexpression in cancers: evidence from a meta-analysis

Cited by 3 publications

References 40 publications

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients

Evaluation of USP22 and Ki-67 expression in oral squamous cell carcinoma: An immunohistochemical study

USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin

Contact Info

Product

Resources

About